Elise M. Walsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elise M. Walsh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Dhyan Chandra
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
7 shared publications Johng S. Rhim
7 shared publicationsNeelu Yadav
7 shared publications- Tariq A. Bhat
Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA
7 shared publications Ajay K. Chaudhary
6 shared publicationsCarl D. Morrison
6 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity.Significance:Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity.Significance:Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Materials and Methods with detailed experimental procedures. Supplemental Table 1 shows the list of antibodies. Supplemental Table 2 shows the list of shRNAs and their sequences. Supplemental Table 3 shows the list of siRNAs and their sources.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Materials and Methods with detailed experimental procedures. Supplemental Table 1 shows the list of antibodies. Supplemental Table 2 shows the list of shRNAs and their sequences. Supplemental Table 3 shows the list of siRNAs and their sources.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Figures - Figure S1 shows CC expression in AA and CA PCa cells. Figure S2 shows cell death and DEVDase activity in AA and CA PCa cells in response to docetaxel treatment. Figure S3 shows effect of CC knockdown on docetaxel-induced apoptotic cell death, caspase-3 and PARP cleavage in CA PCa cells; and mtDNA content in AA and CA PCa cells. Figure S4 shows levels of Nrf1, c-Myc, NF-κB, and PGC-1α in AA and CA PCa cells; and shows cell death, DEVDase activity, and CC expression in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors in AA PCa cells. Figure S5 shows effect of Nrf1 knockdown on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator in AA PCa cells. Figure S6 shows effect of genetic inhibition of c-Myc, NF-κB and PTEN on CC expression and DEVDase activity after docetaxel treatment in AA PCa cells. Figure S7 shows levels of p-Drp1S616 and p-Drp1S637 in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S8 shows effect of Drp1 knockdown on docetaxel-induced DEVDase activity and apoptosis in CA PCa cells. Figure S9 shows knockdown of Drp1 and CC in AA PCa cells and its effect on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator. Figure S10 shows expression levels of oxidative phosphorylation (OXPHOS) complexes III, IV and V in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S11 shows levels of LDHA in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Figures - Figure S1 shows CC expression in AA and CA PCa cells. Figure S2 shows cell death and DEVDase activity in AA and CA PCa cells in response to docetaxel treatment. Figure S3 shows effect of CC knockdown on docetaxel-induced apoptotic cell death, caspase-3 and PARP cleavage in CA PCa cells; and mtDNA content in AA and CA PCa cells. Figure S4 shows levels of Nrf1, c-Myc, NF-κB, and PGC-1α in AA and CA PCa cells; and shows cell death, DEVDase activity, and CC expression in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors in AA PCa cells. Figure S5 shows effect of Nrf1 knockdown on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator in AA PCa cells. Figure S6 shows effect of genetic inhibition of c-Myc, NF-κB and PTEN on CC expression and DEVDase activity after docetaxel treatment in AA PCa cells. Figure S7 shows levels of p-Drp1S616 and p-Drp1S637 in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S8 shows effect of Drp1 knockdown on docetaxel-induced DEVDase activity and apoptosis in CA PCa cells. Figure S9 shows knockdown of Drp1 and CC in AA PCa cells and its effect on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator. Figure S10 shows expression levels of oxidative phosphorylation (OXPHOS) complexes III, IV and V in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S11 shows levels of LDHA in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Figures - Figure S1 shows CC expression in AA and CA PCa cells. Figure S2 shows cell death and DEVDase activity in AA and CA PCa cells in response to docetaxel treatment. Figure S3 shows effect of CC knockdown on docetaxel-induced apoptotic cell death, caspase-3 and PARP cleavage in CA PCa cells; and mtDNA content in AA and CA PCa cells. Figure S4 shows levels of Nrf1, c-Myc, NF-κB, and PGC-1α in AA and CA PCa cells; and shows cell death, DEVDase activity, and CC expression in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors in AA PCa cells. Figure S5 shows effect of Nrf1 knockdown on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator in AA PCa cells. Figure S6 shows effect of genetic inhibition of c-Myc, NF-κB and PTEN on CC expression and DEVDase activity after docetaxel treatment in AA PCa cells. Figure S7 shows levels of p-Drp1S616 and p-Drp1S637 in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S8 shows effect of Drp1 knockdown on docetaxel-induced DEVDase activity and apoptosis in CA PCa cells. Figure S9 shows knockdown of Drp1 and CC in AA PCa cells and its effect on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator. Figure S10 shows expression levels of oxidative phosphorylation (OXPHOS) complexes III, IV and V in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S11 shows levels of LDHA in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Figures - Figure S1 shows CC expression in AA and CA PCa cells. Figure S2 shows cell death and DEVDase activity in AA and CA PCa cells in response to docetaxel treatment. Figure S3 shows effect of CC knockdown on docetaxel-induced apoptotic cell death, caspase-3 and PARP cleavage in CA PCa cells; and mtDNA content in AA and CA PCa cells. Figure S4 shows levels of Nrf1, c-Myc, NF-κB, and PGC-1α in AA and CA PCa cells; and shows cell death, DEVDase activity, and CC expression in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors in AA PCa cells. Figure S5 shows effect of Nrf1 knockdown on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator in AA PCa cells. Figure S6 shows effect of genetic inhibition of c-Myc, NF-κB and PTEN on CC expression and DEVDase activity after docetaxel treatment in AA PCa cells. Figure S7 shows levels of p-Drp1S616 and p-Drp1S637 in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S8 shows effect of Drp1 knockdown on docetaxel-induced DEVDase activity and apoptosis in CA PCa cells. Figure S9 shows knockdown of Drp1 and CC in AA PCa cells and its effect on DEVDase activity in response to docetaxel treatment in the presence of c-Myc and NF-κB inhibitors or AKT activator. Figure S10 shows expression levels of oxidative phosphorylation (OXPHOS) complexes III, IV and V in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients. Figure S11 shows levels of LDHA in primary prostate tumor (PT) and matching non-tumor (MN) tissue samples from AA and CA PCa patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity.Significance:Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity.Significance:Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Materials and Methods with detailed experimental procedures. Supplemental Table 1 shows the list of antibodies. Supplemental Table 2 shows the list of shRNAs and their sequences. Supplemental Table 3 shows the list of siRNAs and their sources.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Supplementary Materials and Methods with detailed experimental procedures. Supplemental Table 1 shows the list of antibodies. Supplemental Table 2 shows the list of shRNAs and their sequences. Supplemental Table 3 shows the list of siRNAs and their sources.
- 11 August 2022
- Published by S. Karger AG in Pathobiology
- Vol. 90 (3) , 199-208
A Comparison of Tissue Dissection Techniques for Diagnostic, Prognostic, and Theragnostic Analysis of Human Disease
Histopathology has historically been the critical technique for the diagnosis and treatment of human disease. Today, genomics, transcriptomics, and proteomics from specific cells, rather than bulk tissue, have become key to understanding underlying disease mechanisms and rendering useful diagnostic information. Extraction of desired analytes, i.e., nucleic acids or proteins, from easily accessible formalin-fixed paraffin-embedded tissues allows for clinically relevant activities, such as sequencing biomarker mutations or typing amyloidogenic proteins. Genetic profiling has become routine for cancers as varied as non-small cell lung cancer and prostatic carcinoma. The five main tissue dissection techniques that have been developed thus far include: bulk scraping, manual macrodissection, manual microdissection, laser-capture microdissection, and expression microdissection. In this review, we discuss the importance of tissue dissection in clinical practice and research, the basic methods, applications, as well as some advantages and disadvantages for each modality.
- 11 August 2022
- Published by S. Karger AG in Pathobiology
- Vol. 90 (3) , 199-208
A Comparison of Tissue Dissection Techniques for Diagnostic, Prognostic, and Theragnostic Analysis of Human Disease
Histopathology has historically been the critical technique for the diagnosis and treatment of human disease. Today, genomics, transcriptomics, and proteomics from specific cells, rather than bulk tissue, have become key to understanding underlying disease mechanisms and rendering useful diagnostic information. Extraction of desired analytes, i.e., nucleic acids or proteins, from easily accessible formalin-fixed paraffin-embedded tissues allows for clinically relevant activities, such as sequencing biomarker mutations or typing amyloidogenic proteins. Genetic profiling has become routine for cancers as varied as non-small cell lung cancer and prostatic carcinoma. The five main tissue dissection techniques that have been developed thus far include: bulk scraping, manual macrodissection, manual microdissection, laser-capture microdissection, and expression microdissection. In this review, we discuss the importance of tissue dissection in clinical practice and research, the basic methods, applications, as well as some advantages and disadvantages for each modality.
- Open Access
- 1 April 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (7) , 1353-1368
Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity. Significance: Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.
- 1 April 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (7) , 1353-1368
Open AccessCytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer
Although African-American (AA) patients with prostate cancer tend to develop greater therapeutic resistance and faster prostate cancer recurrence compared with Caucasian-American (CA) men, the molecular mechanisms of this racial prostate cancer disparity remain undefined. In this study, we provide the first comprehensive evidence that cytochrome c deficiency in AA primary tumors and cancer cells abrogates apoptosome-mediated caspase activation and contributes to mitochondrial dysfunction, thereby promoting therapeutic resistance and prostate cancer aggressiveness in AA men. In AA prostate cancer cells, decreased nuclear accumulation of nuclear respiration factor 1 (Nrf1) and its subsequent loss of binding to the cytochrome c promoter mediated cytochrome c deficiency. The activation of cellular Myc (c-Myc) and NF-κB or inhibition of AKT prevented nuclear translocation of Nrf1. Genetic and pharmacologic inhibition of c-Myc and NF-κB or activation of AKT promoted Nrf1 binding to cytochrome c promoter, cytochrome c expression, caspase activation, and cell death. The lack of p-Drp1S616 in AA prostate cancer cells contributed to defective cytochrome c release and increased resistance to apoptosis, indicating that restoration of cytochrome c alone may be insufficient to induce effective apoptosis. Cytochrome c deficiency promoted the acquisition of glycolytic phenotypes and mitochondrial dysfunction, whereas cytochrome c restoration via inhibition of c-Myc and NF-κB or activation of AKT attenuated glycolysis in AA prostate cancer cells. Inhibition of c-Myc and NF-κB enhanced the efficacy of docetaxel in tumor xenografts. Therefore, restoring cytochrome c may overcome therapeutic resistance and prostate cancer aggressiveness in AA men. Overall, this study provides the first comprehensive experimental, mechanistic, and clinical evidence for apoptosome and mitochondrial dysfunction in prostate cancer racial disparity. Significance: Mechanistic insights on prostate cancer health disparity among American men provide novel approaches to restore mitochondrial function, which can address therapeutic resistance and aggressiveness in African-American men with prostate cancer.